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Methods 
Project I 
 Experimental Autoimmune Encephalomyelitis Mice Model: Female C57BL/6 mice were immunized with MBP 
in Freund’s adjuvant. The mice were weighed and scored daily. At day 10 the mice received either Etomoxir 
(n=21) or placebo (n=21).  
Project II 
 Experimental Autoimmune Encephalomyelitis Rat Model: Female Lewis rats were immunized with MBP in 
Freund’s adjuvant. The rats were weighed and scored daily. At day 1 or day 5 the rats were treated with 
either Etomoxir or Interferon-β (n=10 in each of the five treatment groups). 
 
  
 
 
Background: The pathogenesis of Multiple Sclerosis (MS) involves a new hypothesis concerning 
mitochondrial dysfunction, dysregulated lipid metabolism and inflammation. Carnitine palmitoyl transferase 
1a (CPT1a) is a key molecule involved in lipid metabolism, which is necessary for transport of lipids into 
mitochondria. Lipids are important for the central nervous system as it constitute myelin sheaths and 
thereby shield proteins, e.g. myelin basic protein (MBP), for the immune system. Dysregulated lipid 
metabolism results in changes in concentration and composition of lipids and down regulates glucose 
metabolism, which is the main energy source of the brain. Furthermore, an upregulated lipid metabolism 
results in prostaglandin E2 (PGE2) production, thereby inducing an inflammatory B and T cell response. It 
has been found that B cells start generating antibodies to brain proteins after immunization with MBP 
suggesting a correlation between MS induction and brain antigens. Blocking CPT1a by Etomoxir favours 
glucose metabolism rather than lipid metabolism, thus normalizing lipid levels in the brain, as well as 
downregulating PGE2 production and B cell response. This suggests Etomoxir as an innovative treatment 
strategy for MS.  
 
Methods: Experimental autoimmune encephalomyelitis (EAE) models of MS were established to test the 
efficacy of the CPT1 blocker, Etomoxir. Western Blotting was executed in order to test antibody response 
against brain proteins in EAE animal sera. Antigens recognized by autoantibodies were 
immunoprecipitated and analyzed by mass spectrometry with the purpose to identify these antigens, and 
thereby identifying a correlation between MS and brain antigens.  
 
Results: EAE models of both mice and rats showed 50 % and 25 % healthy animals after treatment with 
Etomoxir. We identified autoantibodies in sera from the EAE animals by an altered antibody response 
between different treatment groups and also isotype of the antibody response. After Etomoxir treatment, 
antibodies to antigens such as apolipoprotein-E, clusterin and serum amyloid P component are i.e. 
recognized and involved in downregulation of the immune system. 
 
Conclusions: Alteration in metabolic pathways is pivotal regarding the pathogenesis of MS, as Etomoxir 
treatment is efficient in treating MS by downregulating lipid metabolism and inflammation. Moreover, 
autoantibodies against brain antigens were identified suggesting a role of these antigens in the progression 
of MS with the potential of using these as biomarkers for MS.  
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Conclusions 
Figure 1. Metabolic pathways in the mitochondria.  
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Examples of Antigens involved in Inflammation 
Results  
A B 
Examples of Antigens involved in Multiple Sclerosis  
Figure 6. Serum antibody intensities of antigens involved in Multiple Sclerosis. Etomoxir treatment revealed significant decreased 
serum antibody intensity to clusterin, serum amyloid P component, apolipoprotein C3 and -2-microglobulin compared to the placebo group. 
Results are presented as mean ± SD. Number of asterisks indicates level of statistical significance (*p=0.01-0.05, **p=0.001-0.01 and 
***p=0.0001-0.001).  
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Etomoxir Blocks Lipid Metabolism in EAE-induced Animals   
Results 
Figure 3. Results from EAE models in mice and rats. 
A-B) EAE mice model. Mean disease score of day 10-24 and percentage of 
healthy animals at day 2. 
 
C-D) EAE rat model. Mean disease score of day 7-11 and percentage of 
healthy animals at day 11. 
 
The statistical analyses applied are two-way RM-ANOVA tests and Chi-square 
tests. Results are presented as mean ± SEM. Number of asterisks indicates 
level of statistical significance (*p=0.01-0.05 and **p=0.001-0.01). 
Project I and II 
 
  
Recognition of Autoantibodies in EAE-induced Animals 
Results 
Figure 4. Recognition of 
autoantibodies. Results from 
Western Blotting showing 
recognition of autoantibodies in 
EAE-induced rat sera. Each 
treatment group (Placebo, 
Interferon- day 1 and 5, and 
Etomoxir day 1 and 5) represents 
two animals each of which are 
tested for IgG, IgG1, IgG2a and 
IgG2b.   
Project III 
Project III 
The project is funded by Aalborg University and the Lundbeck Foundation. We 
thank Meta-IQ ApS for providing Etomoxir.  
New Hypothesis 
 Multiple Sclerosis is a systemic disease caused by dysfunction of lipid 
metabolism and consequently induction of an inflammatory and autoimmune 
response.  
 
Metabolic Pathways 
 Normally, the brain utilizes both glucose and fatty acids for cellular energy 
production (glycolysis and beta-oxidation), whereas in conditions with stress 
the metabolism shifts to lipid utilization (Figure 1). 
 CPT-1 is a key molecule involved in lipid metabolism. 
 Conversion of acyl-CoA to acyl-carnitine by CPT-1 serves as an central 
regulator of the metabolism of the cell. 
Dysregulated Lipid Metabolism 
 Demyelination of neurons leading to exposure of proteins such as Myelin Basic 
Protein (MBP) to immune cells. 
 Recruiting inflammatory cells, which start production of prostaglandin E2 and 
antibodies. 
 Generation of autoantibodies to self-antigens leading to autoimmunity. 
B A 
C D 
Figure 5. Serum antibody intensities to antigens involved in 
inflammation. Alpha-1-acid glycoprotein and alpha-1-inhibitor 3. 
Results are presented as mean ± SD. Number of asterisks indicates 
level of statistical significance (**p=0.001-0.01 and ***p=0.0001-0.001).  
Figure 7. Serum antibody intensities of antigens involved in Multiple Sclerosis. Interferon- treatment resulted in significant 
decreased serum antibody intensity to complement component C9, gelsolin, fibronectin and neural cell adhesion molecule 1 compared to 
the placebo group. Results are presented as mean ± SD. Number of asterisks indicates level of statistical significance (*p=0.01-0.05). 
Project III: 
 Normal rat brain proteins were stained with EAE-induced rat sera by 
Western Blotting. 
 Antigens were immunoprecipitated by antibodies in sera from EAE-induced 
rats and subsequently antigens recognized by autoantibodies were identified 
by mass spectrometry (Figure 2).  
Figure 2. Experimental setup for project III. 
 Blockage of lipid metabolism resulted in 50 % healthy mice and 25 % healthy 
rats. 
 Recognition of brain antigens against autoantibodies revealed: 
 Identification of 35 autoantigens. 
 Identification of modulated autoantibodies against clusterin and 
serum amyloid P component and others after Etomoxir treatment 
compared to placebo. 
 Identification of modulated autoantibodies against complement 
component C9 and gelsolin and others after Interferon- treatment 
compared to placebo. 
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